Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 4/20 | 0.56 |
| ▸ | NSD2 | O96028 | 3/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.54 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.54 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.54 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.54 |
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.51 |
| ▸ | FASN | P49327 | 2/20 | 0.51 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.51 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.51 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.51 |
| ▸ | INMT | O95050 | 1/20 | 0.51 |
| ▸ | PNMT | P11086 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | NNMT | P40261 | 1/20 | 0.51 |
| ▸ | HNMT | P50135 | 1/20 | 0.51 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL8733715 | 1.00 | MARS1 (0.56) | MARS1NSD2CARM1SETD7PRMT1 | |
| Sulfuric Acid SCHEMBL28166953 | 1.00 | MARS1 (0.56) | MARS1NSD2CARM1SETD7PRMT1 | |
| Sulfuric Acid SCHEMBL31277062 | 1.00 | MARS1 (0.56) | MARS1NSD2CARM1SETD7PRMT1 | |
| SCHEMBL635050 | 0.99 | MARS1 (0.57) | MARS1NSD2CARM1SETD7PRMT1 | |
| SCHEMBL29260986 | 0.99 | MARS1 (0.57) | MARS1NSD2CARM1SETD7PRMT1 | |
| SCHEMBL23042225 | 0.99 | MARS1 (0.57) | MARS1NSD2CARM1SETD7PRMT1 | |
| SCHEMBL31197064 | 0.99 | MARS1 (0.57) | MARS1NSD2CARM1SETD7PRMT1 | |
| SCHEMBL19554471 | 0.96 | MARS1 (0.56) | MARS1NSD2CARM1SETD7PRMT1 | |
| Sulfuric Acid SCHEMBL5613159 | 0.93 | MARS1 (0.64) | MARS1NSD2CARM1SETD7PRMT1 | |
| Sulfuric Acid SCHEMBL636869 | 0.93 | MARS1 (0.64) | MARS1NSD2CARM1SETD7PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931356-B2 | Pharmacokinetics of S-adenosylmethionine formulations | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2018-04-03 | — | — | US | disclosed |
| WO-2017192637-A1 | PHARMACEUTICAL COMPOSITION EFFECTIVE IN PREVENTING THE ADVERSE EFFECTS ASSOCIATED WITH THE PROLONGED USE OF DIHYDROFOLATE REDUCTASE INHIBITORS | COMPANION THERAPEUTICS LLC (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20160361339-A1 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | BONAFIDE HEALTH, LLC | 2016-12-15 | — | — | US | disclosed |
| EP-2512490-B1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MSI METHYLATION SCIENCES INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| EP-2464358-B1 | IMPROVED PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | METHYLATION SCIENCES INTERNAT SRL (BB) | 2015-06-17 | — | — | EP | disclosed |
| US-20140370108-A1 | Pharmacokinetics of S-Adenosylmethionine Formulations | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2014-12-18 | — | — | US | disclosed |
| US-8865203-B2 | Pharmacokinetics of S-adenosylmethionine formulations | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2014-10-21 | — | — | US | disclosed |
| WO-2014055932-A1 | INTEGRATED NEUROMODULATION SYSTEM FOR MOOD ENHANCEMENT OF A LIVING HUMAN SUBJECT | INVIVO BEVERAGES LLC (US) | 2014-04-10 | — | — | WO | disclosed |
| US-8580296-B2 | Pharmacokinetics of S-adenosylmethionine formulations | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2013-11-12 | — | — | US | disclosed |
| US-8551515-B2 | — | — | 2013-10-08 | — | — | US | disclosed |
| US-20130142847-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | Methylation Sciences, Inc. (CA) | 2013-06-06 | — | — | US | disclosed |
| US-20130129792-A1 | Pharmacokinetics of S-Adenosylmethionine Formulations | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2013-05-23 | — | — | US | disclosed |
| US-8329208-B2 | Pharmacokinetics of S-adenosylmethionine formulations | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2012-12-11 | — | — | US | disclosed |
| EP-2512490-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MSI Methylation Sciences Inc. (CA) | 2012-10-24 | — | — | EP | disclosed |
| EP-2464358-A2 | IMPROVED PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | Methylation Sciences International SRL (BB) | 2012-06-20 | — | — | EP | disclosed |
| WO-2012012902-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MSI METHYLATION SCIENCES INC. (CA) | 2012-02-02 | — | — | WO | disclosed |
| US-20110027342-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MSI METHYLATION SCIENCES, INC. (CA) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012989-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MSI METHYLATION SCIENCES INC. (CA) | 2011-02-03 | — | — | WO | disclosed |
| US-20110027360-A1 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | METHYLATION SCIENCES INTERNATIONAL SRL (BO) | 2011-02-03 | — | — | US | disclosed |
| WO-2011012990-A2 | IMPROVED PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140370108-A1 | Pharmacokinetics of S-Adenosylmethionine Formulations | MAT1A, MAT2A, AHCY | MARS1 437/4885NSD2 372/4885CARM1 606/4885 |
| US-20130129792-A1 | Pharmacokinetics of S-Adenosylmethionine Formulations | MAT1A, MAT2A, AHCY | MARS1 437/4885NSD2 372/4885CARM1 606/4885 |
| US-20130142847-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MAT2A, MAT1A, BHMT2 | MARS1 276/4885NSD2 413/4885CARM1 256/4885 |
| US-20110027360-A1 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | MAT1A, MAT2A, AHCY | MARS1 437/4885NSD2 372/4885CARM1 606/4885 |
| US-20110027342-A1 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY | MAT1A, MAT2A, BHMT2 | MARS1 335/4885NSD2 526/4885CARM1 406/4885 |
| US-20160361339-A1 | PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS | MAT1A, MAT2A, AHCY | MARS1 437/4885NSD2 372/4885CARM1 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.